Scarica l'app Stockscreener
157.74
1.43%
-2.3006
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$160.04
Aprire:
$158.31
Volume 24 ore:
1.89M
Relative Volume:
0.61
Capitalizzazione di mercato:
$244.66B
Reddito:
$60.48B
Utile/perdita netta:
$10.40B
Rapporto P/E:
47.37
EPS:
3.3297
Flusso di cassa netto:
$8.05B
1 W Prestazione:
-2.40%
1M Prestazione:
-2.28%
6M Prestazione:
-19.08%
1 anno Prestazione:
+94.22%
Intervallo 1D:
$157.25
$159.13
Intervallo di 1 settimana:
$157.25
$165.74
Portata 52W:
$72.89
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Nome
Astrazeneca Plc
Settore
Industria
Telefono
-
Indirizzo
-
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
157.76 | 248.21B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,125.22 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.79 | 648.55B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
249.14 | 439.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.04 | 366.28B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
137.57 | 261.73B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Iniziato | Citigroup | Buy |
| 2025-10-27 | Ripresa | Jefferies | Buy |
| 2025-10-16 | Downgrade | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Outperform |
| 2025-02-13 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-12 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-20 | Aggiornamento | UBS | Sell → Neutral |
| 2024-11-06 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-16 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Sell |
| 2024-01-03 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-09-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-07-12 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-05 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2022-09-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Aggiornamento | Argus | Hold → Buy |
| 2022-06-14 | Downgrade | UBS | Buy → Neutral |
| 2022-02-11 | Aggiornamento | DZ Bank | Sell → Hold |
| 2021-12-07 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-12 | Ripresa | JP Morgan | Overweight |
| 2021-04-12 | Downgrade | Argus | Buy → Hold |
| 2021-03-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-02-25 | Aggiornamento | UBS | Neutral → Buy |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-12-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Aggiornamento | UBS | Sell → Neutral |
| 2020-11-11 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2019-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-10-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-02 | Downgrade | UBS | Neutral → Sell |
| 2019-02-05 | Iniziato | Exane BNP Paribas | Outperform |
| 2019-01-25 | Aggiornamento | Shore Capital | Hold → Buy |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-08-16 | Downgrade | Jefferies | Buy → Hold |
| 2018-03-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-02-06 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-05 | Reiterato | Bernstein | Outperform |
| 2018-01-18 | Reiterato | Leerink Partners | Mkt Perform |
| 2017-12-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
Mostra tutto
Astrazeneca Plc Borsa (AZN) Ultime notizie
AstraZeneca Advances TROP2 Testing Standard in Key Lung Cancer Study - TipRanks
AstraZeneca stock gains analyst support as RBC sets 14,500p target - AD HOC NEWS
AstraZeneca COPD data back Citi's $7b peak sales case - Proactive financial news
RBC Capital Markets Initiates AstraZeneca Coverage at Outperform - marketscreener.com
AstraZeneca stock holds after RBC starts coverage at GBP145 - AD HOC NEWS
NEWSLETTER: AstraZeneca drug reduces lung disease flare-ups in late-stage trials - Reuters
RBC Initiates AstraZeneca at Outperform With GBP145 Price Target - marketscreener.com
Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study - finance.yahoo.com
Amgen and AstraZeneca report survival improvement in lung cancer trial - Yahoo Finance UK
RBC Capital initiates AstraZeneca stock at Outperform, sets target at £145 By Investing.com - Investing.com Canada
RBC Initiates AstraZeneca at Outperform as Near-term Overhangs Create 'Attractive' Entry Point - marketscreener.com
Amgen and AstraZeneca report positive lung cancer trial results By Investing.com - Investing.com Nigeria
AstraZeneca stock edges lower ahead of the open after Imfinzi trial win - AD HOC NEWS
Amgen and AstraZeneca report positive lung cancer trial results - Investing.com
AstraZeneca Stock: What’s Shaping Investor Attention? - Kalkine Media
AstraZeneca stock heads into the open after a 1.2% slide - AD HOC NEWS
FDA clears Astrazeneca's Etcamah for first-line breast cancer - bioworld.com
AstraZeneca PLC : Gets a Buy rating from RBC - marketscreener.com
AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) CongressSlideshow - Seeking Alpha
AstraZeneca stock dips as new cancer and lung trials reshape the pipeline - AD HOC NEWS
AstraZeneca reports tozorakimab COPD trial results - grafa.com
Astrazeneca Secures FDA Approval for New Breast Cancer Treatment - Benzinga
AstraZeneca PLC : Buy rating from JP Morgan - marketscreener.com
ERS 2026: AstraZeneca’s IL-33 inhibitor tozorakimab reduces mucus plug burden in COPD - Pharmaceutical Technology
AstraZeneca's Tozorakimab Shows Promise in COPD Trials, Stock Po - GuruFocus
AstraZeneca and Amgen clear a milestone in small cell lung cancer - marketscreener.com
AstraZeneca’s Lung Disease Drug Shows Broad Benefit in Trials - Bloomberg.com
AstraZeneca's drug combo helps lung cancer patients live longer in late-stage study - London South East
AstraZeneca's Imfinzi Combo Therapy Boosts Survival in Late-stage Small Cell Lung Cancer Study - marketscreener.com
AstraZeneca hails tozorakimab licence application approval in US - London South East
AstraZeneca's cancer drug combo hits main survival goal in late-stage trial - marketscreener.com
AstraZeneca (AZN) says Imfinzi combo extends survival in small cell lung cancer - Stock Titan
AstraZeneca (LSE:AZN) slumps today as combination chatter grips London pharma? - Kalkine Media
REGAstraZeneca PLCImfinzi+Imdelltra improved OS in small cell lung - TradingView
AstraZeneca Says Tozorakimab Cuts COPD Exacerbations in Phase 3 Trials - marketscreener.com
AstraZeneca PLC (AZN.L) stock price, news, quote and history - Yahoo Finance UK
Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell? - Zacks Investment Research
AstraZeneca's Tozorakimab Shows Statistically Significant Efficacy in Late-stage Trials - marketscreener.com
AstraZeneca moves forward in COPD - marketscreener.com
AstraZeneca’s COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes - CNBC
AstraZeneca sees positive result in lung disease drug trial - Breakingthenews.net
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes - CNBC
New AstraZeneca (AZN) breast cancer treatment gets accelerated FDA nod—but only for some patients - Stock Titan
AstraZeneca PLC : Receives a Sell rating from Deutsche Bank - marketscreener.com
AstraZeneca PLC : Barclays maintains a Buy rating - marketscreener.com
AstraZeneca stock heads into the open after a 0.3 percent gain - AD HOC NEWS
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
AstraZeneca stock gains on FDA breast cancer approval and analyst support - AD HOC NEWS
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah - The Globe and Mail
Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval - Proactive financial news
AstraZeneca stock gains on analyst support and July results - AD HOC NEWS
Astrazeneca Plc Azioni (AZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.08%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):